Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „studies“
Suchtreffer
Begriffe & Kennungen
Apixaban Accord · 4.8 · In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in
Eintrag öffnenApixaban Accord · 4.8 · In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced advers
Eintrag öffnenApixaban Accord · 4.8 · In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in
Eintrag öffnenApixaban Accord · 4.8 · The safety of apixaban has been investigated in 1 Phase I and 3 Phase II/III clinical studies including 970 pa
Eintrag öffnenApixaban Accord · 4.8 · The safety of apixaban has been investigated in 1 Phase I and 3 Phase II/III clinical studies including 970 pa
Eintrag öffnenAprovel · 4.5 · 57 Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan i
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAprovel · 4.5 · Additional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan is n
Eintrag öffnenAptivus · 4.5 · 8 In vitro studies show that tipranavir is a substrate and also an inhibitor of P-gp.
Eintrag öffnenAptivus · 4.5 · Interaction studies have only been performed in adults.
Eintrag öffnenAptivus · 4.5 · Studies in human liver microsomes indicated tipranavir is an inhibitor of CYP 1A2, CYP 2C9, CYP 2C19 and CYP 2
Eintrag öffnenAptivus · 4.8 · 24 Tabulated summary of adverse reactions associated with Aptivus based on clinical studies and post- marketin
Eintrag öffnenAquipta · 4.8 · In 12-week, placebo-controlled prophylaxis clinical studies, 678 patients received at least one dose of atogep
Eintrag öffnenAquipta · 4.8 · In placebo-controlled prophylaxis studies, the most commonly reported adverse reactions were nausea (9%), cons
Eintrag öffnenAranesp · 4.8 · Data presented from controlled studies included 1,357 patients, 766 who received Aranesp and 591 patients who
Eintrag öffnenAranesp · 4.8 · In all paediatric CRF studies, there were no additional adverse reactions identified for paediatric patients c
Eintrag öffnenAranesp · 4.8 · Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Eintrag öffnen